On the New Payment-by-Results Method for Determining the Fair Price of New Drugs. An Application in Oncology

Authors

  • Enzo Ballatori Statistico Medico, Spinetoli (AP) - Italy
  • Salvatore Palazzo UOC di Oncologia Medica, Azienda Ospedaliera di Cosenza, Cosenza - Italy
  • Benedetta Ruggeri Governo Clinico, Area Vasta 5, ASUR Marche, Ascoli Piceno - Italy
  • Donatella Morale Oncologia, Area Vasta 5, ASUR Marche, Ascoli Piceno - Italy
  • Aldo Filice UOC di Oncologia Medica, Azienda Ospedaliera di Cosenza, Cosenza - Italy
  • Carmela Oriolo UOC di Farmacia, Azienda Ospedaliera di Cosenza, Cosenza - Italy
  • Alberto Vergati Dipartimento Farmaceutico, Area Vasta 5, ASUR Marche, Ascoli Piceno - Italy
  • Marianna Napoletano Dipartimento Farmaceutico, Area Vasta 5, ASUR Marche, Ascoli Piceno - Italy
  • Isidoro Mazzoni Dipartimento Farmaceutico, Area Vasta 5, ASUR Marche, Ascoli Piceno - Italy

DOI:

https://doi.org/10.33393/grhta.2016.411

Keywords:

Fair price, Payment-by-results, Progression-free survival, Survival distributions

Abstract

A new payment-by-results method, published in a previous issue of this Journal was applied in two Italian oncological centers to show how it is easily implemented. This allowed us to make some considerations concerning clinical oncological research, as well as to draw some conclusions on the possible savings that this approach can deliver to the Italian National Health Service.